Irbesartan in Marfan Syndrome (AIMS): a Double-blind, Placebo-controlled Randomised Trial

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2019 Dec 15

PMID 31836196

Citations 47

Authors

Michael Mullen

Xu Yu Jin

Anne Child

A Graham Stuart

Matthew Dodd

Jose Antonio Aragon-Martin

David Gaze

Anatoli Kiotsekoglou

Li Yuan

Jiangting Hu

Claire Foley

Laura Van Dyck

Rosemary Knight

Tim Clayton

Lorna Swan

John D R Thomson

Guliz Erdem

David Crossman

Marcus Flather

Affiliations

Soon will be listed here.

Abstract

Background: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome.

Methods: We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6-40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794.

Findings: Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12-28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of -0·22 mm per year (-0·41 to -0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means -0·10 per year, 95% CI -0·19 to -0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events.

Interpretation: Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications.

Funding: British Heart Foundation, the UK Marfan Trust, the UK Marfan Association.

Citing Articles

Aortic Remodeling in Patients with Arterial Hypertension: Pathophysiological Mechanisms, Therapeutic Interventions and Preventive Strategies-A Position Paper from the Heart and Hypertension Working Group of the Italian Society of Hypertension.

Mancusi C, Basile C, Fucile I, Palombo C, Lembo M, Buso G High Blood Press Cardiovasc Prev. 2025; .

PMID: 40082374 DOI: 10.1007/s40292-025-00710-3.

Effect of aortic valve phenotype and sex on aorta dilation in patients with aortic stenosis.

Fleury M, Tastet L, Bernard J, Shen M, Capoulade R, Abdoun K Open Heart. 2024; 11(2).

PMID: 39424304 PMC: 11487820. DOI: 10.1136/openhrt-2024-002912.

Exploring the prognostic and diagnostic value of lactylation-related genes in sepsis.

Li S, Shen Y, Wang C, Yang J, Chen M, Hu Y Sci Rep. 2024; 14(1):23130.

PMID: 39367086 PMC: 11452377. DOI: 10.1038/s41598-024-74040-0.

Management of aortic disease in children with FBN1-related Marfan syndrome.

Muino-Mosquera L, Cervi E, De Groote K, Dewals W, Fejzic Z, Kazamia K Eur Heart J. 2024; 45(39):4156-4169.

PMID: 39250726 PMC: 11472455. DOI: 10.1093/eurheartj/ehae526.

MRI-Derived Dural Sac and Lumbar Vertebrae 3D Volumetry Has Potential for Detection of Marfan Syndrome.

Naas O, Norajitra T, Luckerath C, Fink M, Maier-Hein K, Kauczor H Diagnostics (Basel). 2024; 14(12).

PMID: 38928716 PMC: 11202825. DOI: 10.3390/diagnostics14121301.

References

Muino-Mosquera L, De Nobele S, Devos D, Campens L, De Paepe A, De Backer J . Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. Acta Cardiol. 2017; 72(6):616-624. DOI: 10.1080/00015385.2017.1314134. View

Groth K, Stochholm K, Hove H, Andersen N, Gravholt C . Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study). Am J Cardiol. 2018; 122(7):1231-1235. DOI: 10.1016/j.amjcard.2018.06.034. View

Devereux R, de Simone G, Arnett D, Best L, Boerwinkle E, Howard B . Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol. 2012; 110(8):1189-94. PMC: 3462295. DOI: 10.1016/j.amjcard.2012.05.063. View

Gialama F, Maniadakis N . Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan. Vasc Health Risk Manag. 2013; 9:575-92. PMC: 3794869. DOI: 10.2147/VHRM.S50831. View

Shores J, Berger K, Murphy E, Pyeritz R . Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994; 330(19):1335-41. DOI: 10.1056/NEJM199405123301902. View

Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G . Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015; 36(32):2160-6. DOI: 10.1093/eurheartj/ehv151. View

Ladouceur M, Fermanian C, Lupoglazoff J, Edouard T, Dulac Y, Acar P . Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol. 2007; 99(3):406-9. DOI: 10.1016/j.amjcard.2006.08.048. View

Pettersen M, Du W, Skeens M, Humes R . Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr. 2008; 21(8):922-34. DOI: 10.1016/j.echo.2008.02.006. View

Williams A, Davies S, Stuart A, Wilson D, Fraser A . Medical treatment of Marfan syndrome: a time for change. Heart. 2008; 94(4):414-21. DOI: 10.1136/hrt.2006.109454. View

10.

Chiu H, Wu M, Wang J, Lu C, Chiu S, Chen C . Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc. 2013; 88(3):271-6. DOI: 10.1016/j.mayocp.2012.11.005. View

11.

Loeys B, Dietz H, Braverman A, Callewaert B, De Backer J, Devereux R . The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 47(7):476-85. DOI: 10.1136/jmg.2009.072785. View

12.

Neptune E, Frischmeyer P, Arking D, Myers L, Bunton T, Gayraud B . Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003; 33(3):407-11. DOI: 10.1038/ng1116. View

13.

Frost C, Kenward M, Fox N . The analysis of repeated 'direct' measures of change illustrated with an application in longitudinal imaging. Stat Med. 2004; 23(21):3275-86. DOI: 10.1002/sim.1909. View

14.

Pitcher A, Emberson J, Lacro R, Sleeper L, Stylianou M, Mahony L . Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists'.... Am Heart J. 2015; 169(5):605-12. PMC: 4441104. DOI: 10.1016/j.ahj.2015.01.011. View

15.

Mullen M, Flather M, Jin X, Newman W, Erdem G, Gaze D . A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials. 2013; 14:408. PMC: 4220813. DOI: 10.1186/1745-6215-14-408. View

16.

Dietz H, Cutting G, Pyeritz R, Maslen C, Sakai L, Corson G . Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991; 352(6333):337-9. DOI: 10.1038/352337a0. View

17.

Rosenkranz S . TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004; 63(3):423-32. DOI: 10.1016/j.cardiores.2004.04.030. View

18.

Habashi J, Doyle J, Holm T, Aziz H, Schoenhoff F, Bedja D . Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011; 332(6027):361-5. PMC: 3097422. DOI: 10.1126/science.1192152. View

19.

Groenink M, den Hartog A, Franken R, Radonic T, de Waard V, Timmermans J . Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013; 34(45):3491-500. DOI: 10.1093/eurheartj/eht334. View

20.

Bramlage P, Schindler C . Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opin Pharmacother. 2009; 11(4):521-35. DOI: 10.1517/14656560903512962. View